Incyte Corporation (INCY)
Automate Your Wheel Strategy on INCY
With Tiblio's Option Bot, you can configure your own wheel strategy including INCY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INCY
- Rev/Share 24.5981
- Book/Share 23.7706
- PB 4.3171
- Debt/Equity 0.0089
- CurrentRatio 3.1938
- ROIC 0.2074
- MktCap 20146635782.0
- FreeCF/Share 6.1177
- PFCF 16.8304
- PE 16.8938
- Debt/Assets 0.0065
- DivYield 0
- ROE 0.2983
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | INCY | Wells Fargo | Overweight | Equal Weight | -- | $107 | Jan. 20, 2026 |
| Upgrade | INCY | Mizuho | Neutral | Outperform | -- | $121 | Dec. 8, 2025 |
| Upgrade | INCY | Guggenheim | Neutral | Buy | -- | $125 | Nov. 3, 2025 |
| Downgrade | INCY | Oppenheimer | Outperform | Perform | -- | -- | Oct. 8, 2025 |
| Upgrade | INCY | Wells Fargo | Equal Weight | Overweight | -- | $89 | Aug. 6, 2025 |
| Initiation | INCY | Barclays | -- | Overweight | -- | $90 | Aug. 1, 2025 |
| Upgrade | INCY | Stifel | Hold | Buy | -- | $107 | June 16, 2025 |
| Downgrade | INCY | William Blair | Outperform | Market Perform | -- | -- | March 18, 2025 |
| Downgrade | INCY | Guggenheim | Buy | Neutral | -- | -- | March 18, 2025 |
| Initiation | INCY | UBS | -- | Neutral | -- | $77 | Dec. 17, 2024 |
News
Incyte: Buy For The Turnaround, Stay For The Pipeline
Published: January 16, 2026 by: Seeking Alpha
Sentiment: Positive
Incyte Corporation earns a Strong Buy rating, with recent execution driving a 56% stock rally and robust revenue growth. Jakafi sales rose 6.7% YoY in Q3 2025, defying terminal decline fears, while ex-Jakafi business surged 45% YoY. Management projects ex-Jakafi revenues to triple by 2030, with pipeline catalysts and Jakafi XR mitigating the 2028 patent cliff.
Read More
Steven Cress' Top 10 Stocks For 2026
Published: January 15, 2026 by: Seeking Alpha
Sentiment: Positive
Micron Technology (MU) leads Steven Cress' Top 10 Stocks for 2026, driven by sector-leading growth, profitability, and a compelling valuation despite a 254% 1-year return. AI remains a central investment theme, with hyperscalers like MU, AMD, and CIEN benefiting from robust CapEx, strong forward EPS growth, and discounted PEG ratios.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report?
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins
Published: January 06, 2026 by: Seeking Alpha
Sentiment: Positive
Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Monjuvi/Minjuvi and Niktimvo performance. Positive phase 3 frontMIND data for Monjuvi enables a 1st-line DLBCL sBLA filing in H1 2026, expanding addressable market.
Read More
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Neutral
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
Read More
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Published: January 05, 2026 by: Benzinga
Sentiment: Positive
Incyte Corporation (NASDAQ: INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Read More
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral
TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma.
Read More
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral
TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer.
Read More
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
Read More
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: December 17, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma.
Read More
Here's Why Incyte (INCY) is a Strong Value Stock
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack
Published: December 09, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Read More
Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
Published: December 02, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding.
Read More
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Read More
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Incyte (INCY) is a Top Value Stock for the Long-Term
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Incyte Corporation (INCY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation ( INCY ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good morning.
Read More
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners.
Read More
Incyte Corporation (INCY) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation ( INCY ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So welcome to this fireside chat with Incyte.
Read More
Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
Published: November 06, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema.
Read More
Top Biotech Stocks Riding The Rally
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Positive
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launching premature IPOs.
Read More
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
Published: October 28, 2025 by: Benzinga
Sentiment: Positive
Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.
Read More
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
Read More
About Incyte Corporation (INCY)
- IPO Date 1993-11-04
- Website https://www.incyte.com
- Industry Biotechnology
- CEO William Meury
- Employees 2617